IL-DURAVANT
Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced the acquisition of Votech GS B.V. (“Votech”), a leading manufacturer of bag filling machines, palletizer machines, stretch hood machines and pallet transport systems headquartered in Reusel, The Netherlands. Votech will join forces with Fischbein International, a Duravant Operating Company, to serve their global customer base.
The combination of Votech’s expertise in bag management and palletizing and Fischbein’s portfolio of bag sealing and sewing equipment creates a complementary fit between the two companies.
“There is a very complementary relationship between our two organizations,” said Olivier Hancotte, VP and General Manager of Fischbein. “We’re thrilled to work closely with the Votech team to create a broader product offering for both companies’ customers. Fischbein and Votech equipment will both be available through the Fischbein global sales team.”
This partnership brings together two global engineered equipment leaders and extends Duravant’s ability to serve customers and partners in over 190 countries worldwide across multiple sectors including agriculture, industrials, fruit and vegetables, ingredients, pet food and more.
“We’re excited to be a part of the Duravant group of world-class brands and automation solutions,” said Rolf Michiels, Director of Project Sales. “Aligning with the Fischbein team to better serve our customers through a united and collaborative strategy is an exciting prospect for us. Duravant’s lifecycle management via the company’s SupportPro services also gives our customers broader access to value-added solutions that will help their operations achieve their productivity and efficiency goals.”
The Votech brand of packaging machinery has been a competitive force in filling and bag management for over a decade. Votech’s deep engineering and development capabilities allow for the custom design of complete automated solutions from the filling of a bag, to the internal pallet transport to the warehouse. Recognized for superior engineering, package control and local field service support, Votech has proven success delivering packaging solutions for free-flowing and powders applications.
“Our partnership with Duravant opens the path for Votech’s geographic expansion and growth in Europe, the Middle-East, Africa and North America,” adds Pierre Dierckx, Director of Operations. “We’re thrilled to also collaborate with nVenia, Duravant’s US-based operating company serving customers across a wide array of industrial end markets and consumer packaged goods.” The Votech solution set for powders applications is highly complementary with the nVenia product range across primary, secondary and end-of-line packaging.
About Duravant
Headquartered in Downers Grove, IL, Duravant is a global engineered equipment company with manufacturing, sales and service facilities throughout North America, Europe and Asia. Through their portfolio of operating companies, Duravant delivers trusted end-to-end process solutions for customers and partners through engineering and integration expertise, project management and operational excellence. With worldwide sales distribution and service networks, they provide immediate and lifetime aftermarket support to all the markets they serve in the food processing, packaging and material handling sectors. Duravant’s market-leading brands are synonymous with innovation, durability and reliability. For more information, visit www.duravant.com .
About Votech
Headquartered in Reusel, The Netherlands, Votech specializes in developing bag filling and palletizer machines, stretch hood machines and transport systems. The Votech brand has been recognized for providing complete packaging lines from the filling of a bag, through to the internal pallet transport to the warehouse. The entire Votech equipment portfolio is available through Fischbein, a Duravant Company. For more information, visit www.votechbv.co.uk .
About Fischbein
Fischbein designs and manufactures bag packaging equipment and complete systems. For over 100 years, Fischbein has been the leader in sewing and sealing systems by delivering highly engineered, robust and dependable solutions. Serving customers worldwide in agriculture, animal feed, seed, pet food, chemical, mineral, milling, food, building material, medical and pharmaceutical industries, Fischbein has a full range of sealing, filling, weighing, handling, and palletizing equipment that is sold and serviced in more than 190 countries. Fischbein is a Duravant Company. For more information, visit www.fischbein.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005061/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom